Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Are Global Health Care ETFs Worth Prescribing?


Conservative investors and risk-takers alike have been rewarded for owning US health care stocks.

The data supports that assertion. A look at three major health care ETFs, all of which do things a little bit differently, shows significant out-performance of the S&P 500 (INDEXSP:.INX) over various time frames.

For example, the Health Care Select SPDR (NYSEARCA:XLV) is up 30.3% in the past five years compared to 12.3% for the S&P 500.

Since December 2011 when it became a Market Vectors fund, Market Vectors Pharmaceutical ETF (NYSEARCA:PPH) is up almost 20%. The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) has nearly doubled in the past five years.

Bottom line: Investors have done well when staying at home with US health care stocks, but that does not mean there are not global opportunities worth considering. After all, some of the biggest health care companies in the world are not US firms.

France's Sanofi (NYSE:SNY) and Israel's Teva Pharmaceuticals (NASDAQ:TEVA) stand as just two examples.

Here is a look at some international developed market health care ETFs to see if going global with this sector is a better idea than staying domestic.

iShares S&P Global Healthcare Sector Index Fund (NYSEARCA:IXJ): One thing about the iShares S&P Global Healthcare Sector Index Fund that is important to note is that it is a global fund and that means US stocks are included.

Actually, the US might loom too large in IXJ (almost 60% of the ETF's weight), diminishing international exposure in the process. Switzerland is the only other country to land a double-digit allocation in IXJ.

Through the end of last year, IXJ's net asset value had gained 10% over the past three years and 4.3% over the past five, two performance's that are better than ETF's underlying index over the same times, according to iShares data. Obviously, that five-year run does not compare favorably with XLV. In IXJ's favor, it is worth noting the $645 million ETF has a beta of just 0.95 against the S&P 500.

iShares MSCI ACWI ex US Health Care Sector Index Fund (NYSEARCA:AXHE): To take the US out of the health care equation, investors have a few ETF options and one is the iShares MSCI ACWI ex US Health Care Sector Index Fund.

Pharmaceuticals names account for 80% of this fund's weight, leaving only token exposure to health care equipment makers, services providers and biotechnology names.

It is hard to argue with AXHE's composition, though, as the ETF has returned 36.6% since its July 2010. The problem with AXHE is that this is the type of ETF naysayers love to hate. It has less than $13.7 million in assets under management and trades just 2,500 shares per day.

Focusing on those statistics could mean glossing over the fact that plenty of AXHE's 68 holdings can be described as heavily traded, such as Sanofi, Teva and AstraZeneca (NYSE:AZN). Heavy on developed markets, AXHE's has slightly outperformed its index since inception.

SPDR S&P International Health Care Sector ETF (NYSEARCA:IRY): The SPDR S&P International Health Care Sector ETF is the more senior member of the ex-US health care ETF duo, having debuted in July 2008. The $32.5 million fund has returned an admirable 21.6% in the past two years.

While AXHE and IRY both focus heavily on non-US large-cap pharmaceuticals names, there are important differences between the two. For example, IRY is home to 117 holdings compared to 68 for AXHE and the SPDR offering is slightly more expensive with an annual expense ratio of 0.5% compared to 0.48% for AXHE.

Roche (PINK:RHHBY) and Novartis (NYSE:NVS) are the top two holdings in both ETFs, but that pair represents over 25% of AXHE's weight while accounting for 22.4% of IRY's. IRY also features slightly smaller allocations to pharmaceuticals at the sector level and to Switzerland at the country level.

One thing investors might like about IRY over AXHE: A lower beta. IRY's is 0.60 compared to 1.1 on AXHE.

Below, find some more great ETF and market content from Benzinga:

The Fundamental Case for Owning Drone Stocks

Struggling Eurozone Countries Expected to Miss Deficit Targets

Rumor: PlayStation 4 Shipments to Begin Ahead of Schedule

Twitter: @Benzinga

Benzinga Pro covers this and all market news in real time. Get your free trial here.
< Previous
  • 1
Next >
No positions in stocks mentioned.

The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.

Featured Videos